These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 14723112

  • 1. Considerations in the pharmacoeconomics of dry eye.
    Hirsch JD.
    Manag Care; 2003 Dec; 12(12 Suppl):33-8. PubMed ID: 14723112
    [Abstract] [Full Text] [Related]

  • 2. Dry eye symptoms following cataract surgery.
    Roberts CW, Elie ER.
    Insight; 2007 Dec; 32(1):14-21; quiz 22-3. PubMed ID: 17533782
    [Abstract] [Full Text] [Related]

  • 3. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD, Pflugfelder SC, Tauber J, Foulks GN.
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [Abstract] [Full Text] [Related]

  • 4. Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care.
    Chiang TH, Walt JG, McMahon JP, Mansfield JE, Simonyi S.
    Can J Clin Pharmacol; 2007 Oct; 14(2):e240-5. PubMed ID: 17622671
    [Abstract] [Full Text] [Related]

  • 5. Utilization characteristics of topical cycolsporine and punctal plugs in a managed care database.
    Fiscella RG, Lee JT, Walt JG, Killian TD.
    Am J Manag Care; 2008 Apr; 14(3 Suppl):S107-12. PubMed ID: 18452370
    [Abstract] [Full Text] [Related]

  • 6. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
    Hom MM.
    Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM, McGwin G, Liu B, Owsley C, Rosenstiel C.
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [Abstract] [Full Text] [Related]

  • 8. Restasis use in the chronic dry eye patient.
    Bataoel A.
    Insight; 2007 Jan; 32(3):21. PubMed ID: 17953324
    [No Abstract] [Full Text] [Related]

  • 9. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
    Kim EC, Choi JS, Joo CK.
    Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318
    [Abstract] [Full Text] [Related]

  • 10. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome.
    Brown MM, Brown GC, Brown HC, Peet J, Roth Z.
    Arch Ophthalmol; 2009 Feb; 127(2):146-52. PubMed ID: 19204231
    [Abstract] [Full Text] [Related]

  • 11. United States cost-effectiveness study of two dry eye ophthalmic lubricants.
    Wlodarczyk J, Fairchild C.
    Ophthalmic Epidemiol; 2009 Feb; 16(1):22-30. PubMed ID: 19191178
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM, McDonald MB, Smolek M.
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [Abstract] [Full Text] [Related]

  • 13. Dry eye moves beyond palliative therapy.
    Sheppard JD.
    Manag Care; 2003 Dec; 12(12 Suppl):6-8. PubMed ID: 14723107
    [Abstract] [Full Text] [Related]

  • 14. [Effect of anti-inflammatory therapy on the treatment of dry eye syndrome].
    Mrukwa-Kominek E, Rogowska-Godela A, Gierek-Ciaciura S.
    Klin Oczna; 2007 Dec; 109(1-3):79-84. PubMed ID: 17687921
    [Abstract] [Full Text] [Related]

  • 15. Clinical and economic implications of topical cyclosporin A for the treatment of dry eye.
    Cross WD, Lay LF, Walt JG, Kozma CM.
    Manag Care Interface; 2002 Sep; 15(9):44-9. PubMed ID: 12244650
    [Abstract] [Full Text] [Related]

  • 16. Prevalence, burden, and pharmacoeconomics of dry eye disease.
    Pflugfelder SC.
    Am J Manag Care; 2008 Apr; 14(3 Suppl):S102-6. PubMed ID: 18452369
    [Abstract] [Full Text] [Related]

  • 17. Cyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in children.
    Hoehn ME, Kelly SR, Wilson MW, Walton RC.
    Pediatr Blood Cancer; 2013 Jul; 60(7):E35-7. PubMed ID: 23335290
    [Abstract] [Full Text] [Related]

  • 18. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME.
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [Abstract] [Full Text] [Related]

  • 19. Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye.
    Khanal S, Tomlinson A, Pearce EI, Simmons PA.
    Cornea; 2007 Feb; 26(2):175-81. PubMed ID: 17251808
    [Abstract] [Full Text] [Related]

  • 20. Ophthalmic cyclosporine use in ocular GVHD.
    Lelli GJ, Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI.
    Cornea; 2006 Jul; 25(6):635-8. PubMed ID: 17077652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.